<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LYSODREN- mitotane tablet </strong><br>E.R. Squibb &amp; Sons, L.L.C.<br></p></div>
<h1>
<span class="Bold">LYSODREN<span class="Sup">®</span></span><br><span class="Bold">(mitotane tablets, USP)</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">LYSODREN (mitotane tablets, USP) should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents. LYSODREN should be temporarily discontinued immediately following <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or severe <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> since adrenal suppression is its prime action. Exogenous steroids should be administered in such circumstances, since the depressed adrenal may not immediately start to secrete steroids.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">LYSODREN<span class="Sup">®</span> (mitotane tablets, USP) is an oral chemotherapeutic agent. It is best known by its trivial name, o,p′-DDD, and is chemically, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl) ethane. The chemical structure is shown below:</p>
<div class="Figure">
<a name="id269"></a><img alt="Mitotane Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e9fba7d4-a0ec-4bfa-9b5b-ec97a9710fd3&amp;name=lysodren-struct.jpg">
</div>
<p>LYSODREN is a white granular solid composed of clear colorless crystals. It is tasteless and has a slight pleasant aromatic odor. It is soluble in ethanol, isooctane, and carbon tetrachloride. It has a molecular weight of 320.05.</p>
<p>Inactive ingredients in LYSODREN tablets are: avicel, Polyethylene Glycol 3350, silicon dioxide, and starch.</p>
<p>LYSODREN is available as 500 mg scored tablets for oral administration.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">LYSODREN can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. Its biochemical mechanism of action is unknown. Data are available to suggest that the drug modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex. The administration of LYSODREN alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>. The drug apparently causes increased formation of 6-β-hydroxycortisol.</p>
<p>Data in adrenal carcinoma patients indicate that about 40% of oral LYSODREN is absorbed and approximately 10% of the administered dose is recovered in the urine as a water-soluble metabolite. A variable amount of metabolite (1%-17%) is excreted in the bile and the balance is apparently stored in the tissues.</p>
<p>Following discontinuation of LYSODREN, the plasma terminal half-life has ranged from 18 to 159 days. In most patients blood levels become undetectable after 6 to 9 weeks. Autopsy data have provided evidence that LYSODREN is found in most tissues of the body; however, fat tissues are the primary site of storage. LYSODREN is converted to a water-soluble metabolite.</p>
<p>No unchanged LYSODREN has been found in urine or bile.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">LYSODREN is indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">LYSODREN (mitotane tablets, USP) should not be given to individuals who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">LYSODREN should be temporarily discontinued immediately following <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> or severe <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, since adrenal suppression is its prime action. Exogenous steroids should be administered in such circumstances, since the depressed adrenal may not immediately start to secrete steroids.</p>
<p>LYSODREN should be administered with care to patients with liver disease other than metastatic lesions from the adrenal cortex, since the metabolism of LYSODREN may be interfered with and the drug may accumulate.</p>
<p>All possible tumor tissues should be surgically removed from large metastatic <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span> before LYSODREN administration is instituted. This is necessary to minimize the possibility of <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> in the tumor due to a rapid cytotoxic effect of the drug.</p>
<p>Long-term continuous administration of high doses of LYSODREN may lead to <span class="product-label-link" type="condition" conceptid="4080670" conceptname="Brain damage">brain damage</span> and impairment of function. Behavioral and neurological assessments should be made at regular intervals, since toxicity may be reversible after discontinuation of LYSODREN. Literature reports suggest that mitotane plasma concentrations exceeding 20 mcg/mL are associated with a greater incidence of high grade central nervous system toxicity.</p>
<p>A substantial percentage of the patients treated show signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. It therefore appears necessary to watch for and institute steroid replacement in those patients. However, some investigators have recommended that steroid replacement therapy be administered concomitantly with LYSODREN. It has been shown that the metabolism of exogenous steroids is modified and consequently somewhat higher doses than normal replacement therapy may be required. Since LYSODREN increases hormone binding proteins, measurement of free cortisol and corticotropin (ACTH) levels may be useful in achieving optimal steroid replacement.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s7.1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> may develop in patients treated with LYSODREN, and adrenal steroid replacement should be considered for these patients.</p>
<p>Since sedation, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, and other CNS side effects can occur, ambulatory patients should be cautioned about driving, operating machinery, and other hazardous pursuits requiring mental and physical alertness.</p>
<p>Prolonged <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> has been reported in patients treated with LYSODREN. Consider this possibility prior to any <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7.2"></a><a name="section-6.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">LYSODREN is a strong inducer of cytochrome P-450 3A4 (CYP3A4). Monitor patients for a change in dosage requirements for the concomitant drug when administering LYSODREN to patients receiving drugs that are substrates of CYP3A4. </p>
<p>LYSODREN’s CYP induction effect leads to an increase in dosage requirements for warfarin. Closely monitor patients for a change in anticoagulant dosage requirements when administering LYSODREN to patients receiving coumarin-type anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s7.3"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">The carcinogenic and mutagenic potentials of LYSODREN (mitotane tablets, USP) are unknown. However, the mechanism of action of this compound suggests that it probably has less carcinogenic potential than other cytotoxic chemotherapeutic drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7.4"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy </h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_d0479bae-d94e-4b16-a8e5-13db1514bf5f"></a><a name="section-6.4.1"></a><p></p>
<h3>Pregnancy Category D</h3>
<p class="First">LYSODREN can cause fetal harm when administered to a pregnant woman. Abnormal pregnancy outcomes such as preterm births and early pregnancy loss have been reported in patients exposed to mitotane during pregnancy. Animal reproduction studies have not been conducted with LYSODREN. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.</p>
<p>Advise women of childbearing potential to use effective contraception during treatment and after discontinuation of treatment for as long as mitotane plasma levels are detectable (see <span class="Bold">CLINICAL PHARMACOLOGY</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s7.5"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Mitotane has been detected in breast milk. Because of the potential for serious adverse reactions in nursing infants from mitotane, advise women to discontinue nursing during LYSODREN therapy and after treatment discontinuation for as long as mitotane plasma levels are detectable (see <span class="Bold">CLINICAL PHARMACOLOGY</span>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s7.6"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s7.7"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of LYSODREN did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s8"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">A very high percentage of patients treated with LYSODREN have shown at least one type of side effect. The main types of adverse reactions consist of the following:</p>
<dl>
<dt>1.</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disturbances</span>, which consist of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and in some cases <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, occur in about 80% of the patients.</dd>
<dt>2.</dt>
<dd>Central nervous system side effects occur in 40% of the patients. These consist primarily of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> as manifested by <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (25%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> (15%).</dd>
<dt>3.</dt>
<dd>Skin toxicity has been observed in about 15% of the cases. These skin changes consist primarily of transient <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> which do not seem to be dose related. In some instances, this side effect subsided while the patients were maintained on the drug without a change of dose.</dd>
</dl>
<p>Infrequently occurring side effects involve the eye (visual blurring, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">lens opacity</span>, toxic <span class="product-label-link" type="condition" conceptid="376103" conceptname="Retinopathy">retinopathy</span>); the genitourinary system (<span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>, and <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>); cardiovascular system (<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>); and some miscellaneous effects including <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">generalized aching</span>, <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, and lowered protein bound iodine (PBI).</p>
<p>The following additional adverse reactions have been identified during postapproval use of LYSODREN. Because reports are voluntary from a population of unknown size, an estimate of frequency cannot be made.</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span></p>
<p><span class="Italics">Psychiatric disorders:</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>:</span> neuropsychological disturbance, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4208223" conceptname="Disorder of macula of retina">maculopathy</span> </p>
<p><span class="Italics">Hepatobiliary disorders:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, elevation of liver enzymes </p>
<p><span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<p><span class="Italics">General disorders and administration site conditions:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p>
<p><span class="Italics">Investigations: </span>blood uric acid decreased, blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased, blood triglycerides increased</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No proven antidotes have been established for LYSODREN overdosage. The long half-life of mitotane will require prolonged observation for toxicity (see <span class="Bold">CLINICAL PHARMACOLOGY</span>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended treatment schedule is to start the patient at 2 g to 6 g of LYSODREN per day in divided doses, either 3 or 4 times a day. Doses are usually increased incrementally to 9 g to 10 g per day. If severe side effects appear, the dose should be reduced until the maximum tolerated dose is achieved. If the patient can tolerate higher doses and improved clinical response appears possible, the dose should be increased until adverse reactions interfere. Experience has shown that the maximum tolerated dose (MTD) will vary from 2 g to 16 g per day, but has usually been 9 g to 10 g per day. The highest doses used in the studies to date were 18 g to 19 g per day.</p>
<p>Treatment should be instituted in the hospital until a stable dosage regimen is achieved.</p>
<p>Treatment should be continued as long as clinical benefits are observed. Maintenance of clinical status or slowing of growth of metastatic lesions can be considered clinical benefits if they can clearly be shown to have occurred.</p>
<p>If no clinical benefits are observed after 3 months at the maximum tolerated dose, the case would generally be considered a clinical failure. However, 10% of the patients who showed a measurable response required more than 3 months at the MTD. Early diagnosis and prompt institution of treatment improve the probability of a positive clinical response. Clinical effectiveness can be shown by reduction in tumor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>; reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>; and reduction of symptoms and signs due to excessive steroid production.</p>
<p>A number of patients have been treated intermittently with treatment being restarted when severe symptoms have reappeared. Patients often do not respond after the third or fourth such course. Experience accumulated to date suggests that continuous treatment with the maximum possible dosage of LYSODREN is the best approach.</p>
<p>Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.<span class="Sup">1</span></p>
<p>To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing LYSODREN tablets. LYSODREN tablets should not be crushed. Personnel should avoid exposure to crushed and/or broken tablets. If contact with broken tablets occurs, wash immediately and thoroughly. More information is available in the references listed below.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">LYSODREN<span class="Sup">®</span> (mitotane tablets, USP)</p>
<p><span class="Bold">NDC</span> 0015-3080-60—500 mg Tablets, bottle of 100</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s11.1"></a><a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s12"></a><a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-12"></a><p></p>
<p class="First">Manufactured for: <br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543 USA<br></p>
<p>1332113<br>Rev November 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_43a7f778-2001-440d-ac4f-9eaf4f8dd7f0"></a><a name="section-13"></a><p></p>
<h1>----------------------------------------------<br><span class="Bold">REPRESENTATIVE PACKAGING</span>
</h1>
<p class="First">See <span class="Bold">How Supplied</span> section for a complete list of available packages of LYSODREN.</p>
<p><span class="Bold">NDC 0015-3080-60</span><br><span class="Bold">100 TABLETS</span><br><span class="Bold">LYSODREN<span class="Sup">®</span> (mitotane tablets, USP)</span><br>EACH TABLET CONTAINS<span class="Bold"> 500 mg </span><br><span class="Bold">Rx only</span><br>Bristol-Myers Squibb</p>
<div class="Figure">
<a name="id23393658"></a><img alt="Lysodren 500 mg Tablets Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e9fba7d4-a0ec-4bfa-9b5b-ec97a9710fd3&amp;name=500mg-btl-lbl.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LYSODREN 		
					</strong><br><span class="contentTableReg">mitotane tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0015-3080</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>mitotane</strong> (mitotane) </td>
<td class="formItem">mitotane</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 3350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BL;L1</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0015-3080-60</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016885</td>
<td class="formItem">06/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>E.R. Squibb &amp; Sons, L.L.C.
							(968242821)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1b5c2018-656a-4dce-99c4-315cfc28c43b</div>
<div>Set id: e9fba7d4-a0ec-4bfa-9b5b-ec97a9710fd3</div>
<div>Version: 7</div>
<div>Effective Time: 20131129</div>
</div>
</div> <div class="DistributorName">E.R. Squibb &amp; Sons, L.L.C.</div></p>
</body></html>
